Drug intelligence / Profile preview

Curalin

Development stage: Unknown
Lead developer: NutraStar
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

CuraLin is a multi-ingredient herbal dietary supplement developed by CuraLife for the management of Type 2 Diabetes Mellitus. It is formulated as a blend of nine Ayurvedic herbs, including *Syzygium cumini*, *Gymnema sylvestre*, *Momordica charantia*, and *Trigonella foenum-graecum*. The supplement is intended to improve glycemic control, reduce HbA1c levels, and support healthy glucose metabolism as an add-on therapy to standard anti-diabetic drugs. Clinical studies have demonstrated significant reductions in HbA1c and high patient satisfaction with a favorable safety profile.

Brand names: CuraLin
Other names: CuraLin

Beyond the preview

Go deeper on Curalin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curalin.

Explore the full profile